Masimo (NASDAQ:MASI) Issues FY 2025 Earnings Guidance

Key Points

• Masimo has issued FY 2025 earnings guidance with EPS expectations ranging from $5.450 to $5.700, outperforming the consensus estimate of $4.976.
• The company also provided revenue guidance of $1.5 billion, matching analysts' consensus revenue estimates.
• Masimo's stock saw an increase of 3.9%, with a consensus rating of "Moderate Buy" and an average target price of $193.60.

Masimo (NASDAQ:MASI - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 5.450-5.700 for the period, compared to the consensus EPS estimate of 4.976. The company issued revenue guidance of $1.5 billion-$1.5 billion, compared to the consensus revenue estimate of $1.5 billion.

Masimo Stock Up 3.9%

NASDAQ MASI opened at $155.96 on Thursday. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.61 and a current ratio of 2.14. The company has a market capitalization of $8.47 billion, a P/E ratio of -18.31 and a beta of 1.21. Masimo has a one year low of $107.98 and a one year high of $194.88. The stock has a 50 day moving average price of $161.70 and a 200-day moving average price of $164.24.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.22 by $0.11. The company had revenue of $370.90 million during the quarter, compared to the consensus estimate of $368.65 million. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%. Masimo's revenue was up 7.7% on a year-over-year basis. During the same period last year, the company earned $0.86 earnings per share. As a group, equities analysts predict that Masimo will post 4.1 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on MASI shares. BTIG Research reiterated a "buy" rating on shares of Masimo in a research note on Monday, July 14th. Wells Fargo & Company reduced their target price on Masimo from $205.00 to $190.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Wall Street Zen lowered Masimo from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Piper Sandler increased their target price on Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Finally, Raymond James Financial reduced their target price on Masimo from $204.00 to $185.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $193.60.

Insider Activity at Masimo

In other news, Director William R. Jellison purchased 3,000 shares of the business's stock in a transaction dated Monday, August 11th. The shares were purchased at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the purchase, the director owned 4,790 shares in the company, valued at approximately $699,244.20. This represents a 167.60% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 9.70% of the company's stock.

Hedge Funds Weigh In On Masimo

Several institutional investors have recently made changes to their positions in the company. California Public Employees Retirement System increased its stake in shares of Masimo by 4.2% during the second quarter. California Public Employees Retirement System now owns 72,807 shares of the medical equipment provider's stock valued at $12,248,000 after buying an additional 2,932 shares during the period. Amundi increased its stake in shares of Masimo by 1.0% during the second quarter. Amundi now owns 41,583 shares of the medical equipment provider's stock valued at $7,125,000 after buying an additional 416 shares during the period. Quantbot Technologies LP purchased a new position in shares of Masimo during the second quarter valued at $86,000. Goldman Sachs Group Inc. boosted its position in Masimo by 38.6% during the first quarter. Goldman Sachs Group Inc. now owns 280,255 shares of the medical equipment provider's stock valued at $46,690,000 after purchasing an additional 78,003 shares in the last quarter. Finally, Jones Financial Companies Lllp boosted its position in Masimo by 1,267.1% during the first quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider's stock valued at $367,000 after purchasing an additional 2,040 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company's stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.